Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v18.i6.40
16 pages

In Vivo Applications of PEG Liposomes: Unexpected Observations

Peter Laverman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Otto C. Boerman
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Wim J. G. Oyen
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Frans H. M. Corstens
Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands
Gert Storm
Utrecht Institute for Pharmaceutical Science, Utrecht University, Utrecht, The Netherlands

ABSTRAKT

Recent studies with PEG liposomes in patients have consistently shown that liposomes can induce side effects (flushing, tightness of the chest). Furthermore, the blood clearance of PEG liposomes was shown to be dose-dependent: at lipid doses lower than 1 mmol/kg, PEG liposomes do not show the long-circulation property but instead are cleared relatively rapidly from the bloodstream. Another remarkable observation was that repeated injections of PEG liposomes led to significant pharmacokinetic changes: the circulatory half-life of a second dose of radiolabeled PEG liposomes dramatically decreased when given from 5 days to up to 4 weeks after a first injection. In these three unexpected phenomena, proteins of the complement system seem to play a key role.Therefore, one has to consider that PEG liposomes are not inert drug-carrying vehicles in vivo. Pharmacological effects can occur, induced solely by using liposomal particles irrespective of the drug content.


Articles with similar content:

A Randomized, Placebo-Controlled, Multicenter Study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Polysaccharides (Ganopoly®) in Patients with Advanced Lung Cancer
International Journal of Medicinal Mushrooms, Vol.5, 2003, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Supplementation with a Soluble Beta-Glucan Exported from Shiitake Medicinal Mushroom, Lentinus edodes (Berk.) Singer Mycelium: a Crossover, Placebo-Controlled Study in Healthy Elderly
International Journal of Medicinal Mushrooms, Vol.13, 2011, issue 4
Jowita Sleboda, Minna Nurminiemi, Elling Ulvestad, Ola Gudmundsen, Cecilie Moe, Jean-Michel Gaullier, Erik Snorre Ofjord, Tor Albrektsen
Particulate Pulmonary Delivery Systems Containing Anti-Tuberculosis Agents
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Mradul Mohan, Imran Mohammad, Atul Kumar Agrawal, Sanketkumar M. Pandya, Amit Misra, Anuradha Gupta
Clinical Trials for Medicinal Mushrooms: Experience with Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Lingzhi Mushroom)
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 1&2
Yihuai Gao, Eli Chan, Shufeng Zhou
Liposomal Formulations of Cyclosporin A: A Biophysical Approach to Pharmacokinetics and Pharmacodynamics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.18, 2001, issue 2
J. Seelig, A. Fahr